Upstream versus downstream inhibition of Gram-negative induced inflammation by Barratt-Due, Andreas
1Upstream versus downstream inhibition of 
Gram-negative induced inflammation
PhD Thesis
Andreas Barratt-Due
2012
Department of Immunology
Institute of Clinical Medicine
Oslo University Hospital Rikshospitalet and
Faculty of Medicine
University of Oslo
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Andreas Barratt-Due, 2012 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 1415 
 
ISBN 978-82-8264-501-0 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AIT Oslo AS.  
 
Produced in co-operation with Akademika publishing.  
The thesis is produced by Unipub merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 
3Acknowledgement
Research is stimulating. It gives the opportunity and time to pursue a line of thought and 
engage in intellectual processes. The complexity of innate immunity and its numerous 
biological functions have fascinated me profoundly, and the work starting January 2008 has 
certainly been a truly positive experience. Furthermore, the work with this Thesis has brought 
me in contact with highly skilled persons and researchers, with whom it has been exceedingly 
stimulating to work and collaborate. Without their help and support, this Thesis could not 
have been carried out.
First and foremost, my appreciation goes to my supervisor, Professor Tom Eirik Mollnes. His 
dedication to science, his enormous capacity for work, his enthusiasm, curiosity and ability to 
always see and find solutions are qualities that have inspired me and guided my work. His 
availability cannot be underestimated, as he literally at all hours, weekends and holidays, has 
been open for questions and discussions. It has been a privilege to be supervised by him, and 
it has indisputably been a true education in science.
A special thank goes to my co-supervisor, Ebbe Billmann Thorgersen, for excellent feedback 
on papers and companion discussions, and to Professor Erik Waage Nielsen for a very fruitful 
collaboration and for steadily guiding me through the icatibant study. A warm thank goes to 
the technicians, Anne Pharo and Julie Katrine Lindstad. Patiently they have introduced me to 
lab work. Their everyday presence and skilled knowledge have been invaluable for all the 
different projects, and not least have made the days at the Institute very pleasant. Søren 
Pischke, Bernt Christian Hellerud, Andrey Sokolov, Kjetil Egge, Alice Gustavsen, Albert 
Castellheim and Professor Emeritus Morten Harboe are all members of the Complement 
group, and have in different ways given me help and assistance. Thanks to you all.
Thanks to Professor Harald Thidemann Johansen and Knut Fredrik Seip at the Department of 
Pharmacy, University of Oslo, for the massive work related to BK1-5 measurements and 
interpretation of data.   
Thanks to Kjersti Wendt, Carmen Louwerence and Brita Nordland at the Interventional 
Center, Rikshospitalet for helping and facilitating the in vivo experiments.
4The work of this Thesis has been conducted at the Institute of Immunology, Oslo University 
Hospital Rikshospitalet. It has been founded by scholarship from the Medinnova foundation, 
Helse Sør-Øst and the Research Council of Norway. I am grateful for the provided financial 
support and to the University of Oslo for giving me this opportunity. I would also thank the 
Department of Anaesthesiology and Intensiv Care Medisin, Rikshospitalet, for giving me the 
opportunity to work part time while I have been engaged in research. 
Finally, I thank my amazing wife, Nina, for supporting me in completing this Thesis. Her 
ability to run the family, solve everyday logistical challenges in my physical and mental 
absence, and even reading and commenting my work, has been crucial. When all is said and 
done, nothing is more important than you and our family. 
Oslo, June 2012
5TABLES OF CONTENTS
LIST OF PAPERS 7
SELECTED ABBREVIATIONS 8
INTRODUCTION 10
Inflammation 10
Innate Immunity 11
 The complement system 13
o The anaphylatoxins of complement 15
 Toll-like receptors 16
o CD14 – the key accessory molecule 17
 Hemostasis and contact activation 18
 Cross-talk and redundancy of host defense 19
Sepsis 19
 Definition 19
 Sepsis epidemiology 20
 Innate Immunity and sepsis pathophysiology 21
AIM 23
MATERIALS AND METHODS 24
Introduction 24
Bacteria and activators 24
Inhibitors 25
Analyses 25
 Enzyme immunoassay and multiplex technology 25
 Flow cytometry 26
 Determination of BK1-5 level and icatibant 27
6 Histopathological evaluation 27
Models 27
 Ex vivo whole blood model 27
 In vivo models 28
Statistical considerations 30
SUMMARY OF MAIN RESULTS 31
Paper I 31
Paper II 31
Paper III 32
Paper IV 33
DISCUSSION 34
Upstream and downstream 34
 Downstream inhibition 34
 Upstream inhibition 35
Single-mediator inhibition 37
Complement inhibition and pigs 38
Different roles of complement and CD14 39
The in vivo models and intervention principle 41
The translational advantage of the in vivo models 43
Future perspectives 45
CONCLUSION 47
REFERENCES 48
Paper I-IV 62
7LIST OF PAPERS
Study I
Barratt-Due A., E.B. Thorgersen, J.K. Lindstad, A. Pharo, O.L. Brekke, D. Christiansen, J.D. 
Lambris, T.E. Mollnes. 2010. Selective inhibition of TNF- or IL-1 does not affect E. coli-
induced inflammation in human whole blood. Mol.Immunol.47:1774-82
Study II
Barratt-Due A., H.T. Johansen, A. Sokolov, E.B. Thorgersen, B.C. Hellerud, J.L. Reubsaet, 
K. F. Seip, T.I. Tønnessen, J.K. Lindstad, A. Pharo, A. Castellheim, T.E. Mollnes, E.W. 
Nielsen. 2011. The role of bradykinin and the effect of the bradykinin receptor antagonist 
icatibant in porcine sepsis. Shock 36:517-23
Study III
Barratt-Due A., E.B. Thorgersen, J.K. Lindstad, A. Pharo, O. Lissina, J.D. Lambris, M.A. 
Nunn, T.E. Mollnes. 2011. Ornithodoros moubata complement inhibitor (OmCI) is an equally 
effective C5 inhibitor in pig and human. J.Immunol.187:4913-19
Study IV
Barratt-Due A., K. Egge, E.B. Thorgersen, A. Sokolov, B.C. Hellerud, S. Pischke, J.K. 
Lindstad, A. Pharo, M.A. Nunn, H. Scott, T.E. Mollnes. Combined inhibition of Complement 
(C5) and CD14 attenuates inflammation, trombogenicity and hemodynamic changes in 
porcine sepsis. Submitted
8SELECTED ABBREVIATIONS
Ab Antibody
AP Alternative Pathway
BK Bradykinin
CLP Cecal Ligation and Puncture
CP Classical Pathway
CR1 Complement Receptor 1
CR3 Complement Receptor 3
C3aR C3a Receptor
C5aR C5a Receptor
DIC Disseminated Intravascular Coagulation
E. coli Escherichia coli
EIA Enzyme Immunoassay
ICU Intensive Care Unit
Ig Immunoglobulin
IL Interleukin
LP Lectin Pathway
LPS Lipoplysaccharide
LTB4 Leukotriene B4 
MAP Mean Arterial Pressure
MBL Mannose Binding Lectin
MFI Median Fluorescence Intensity
MOF Multiple Organ Failure
mg Milligram
mL Milliliter
mM Millimolar
mmol Millimol
MPAP Mean Pulmonary Arterial Pressure
MyD88 Myeloid Differentiation Primery Response Gene 88
NF- Nuclear Factor kappa-light-chain-enhancer of activated B cells
OmCI Ornithodors moubata Complement Inhibitor
PAI-1 Plasminogen Activator Inhibitor
PBS Phosphate Buffer Saline
9RA Ringer Acetate
SIRS Systemic Inflammatory Response Syndrom
SVRI Systemic Vascular Resistance Index
TAT Thrombin-Antithrombin Complex
TCC Terminal Complement Complex
TF Tissue Factor
TNF- 	

		

TLR Toll-Like Receptor 
10
INTRODUCTION
Throughout history, infectious disease has been a leading cause of death in humans. 
Descriptions of sepsis date back to antiquity. Hippocrates viewed it as evil and as a dangerous 
biological decay (1). The word “sepsis” derives from Greek, and refers to decomposition of 
animal or organic matter in the presence of bacteria (2). Our perspectives and, not least,
knowledge have thereafter changed, but despite the entry of antibiotics, sepsis represents 
danger and is still a major challenge and a significant cause of morbidity and mortality.
During the last part of the twentieth century, an improved understanding of sepsis 
pathophysiology and molecular mechanisms, including the host immune response, has 
emerged. One prevailing theory has been that sepsis represents an uncontrolled host-
inflammatory response, as clearly formulated by L. Thomas in 1972:
The micro-organisms that seem to have it in for us […] turn out on close examination
to be rather more like bystanders […] it is our response to their presence that makes 
the disease. Our arsenals for fighting off bacteria are so powerful […] that we are in 
more danger from them than the invaders (3).
Hence, one of the main tasks in sepsis-related research has been to intervene and inhibit the 
detrimental effects of the excessive host-inflammatory response. Our growing understanding 
of innate immunity and its capacity to respond effectively on exogenous as well as 
endogenous danger has made it particularly interesting as a target for intervention. In this 
Thesis I will present the work done by colleagues and myself, on different target strategies in 
Gram-negative induced inflammation and sepsis.
Inflammation
Inflammation is primarily a protective immune response trying to restore homeostasis. The
inflammatory pathways can be divided into inducers, sensors, mediators and effectors (4),
which is helpful when trying to dissect and distinguish between complex networks of 
mediators and cascade systems that participate in these reactions. Different inducers initiate 
the inflammatory response by activating specialized sensors leading to the release of different 
mediators such as cytokines and subsequent effects. Bacteria and viruses are classical
exogenous inducers, but endogenous inducers derived from tissue injury, tissue hypoxemia or 
other kinds of tissue stress or malfunction might well trigger the host response. Regardless of 
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the cause, these processes are followed by vascular dilatation, capillary leakage and 
recruitment of mediators and different cells. The short-term process of acute inflammation 
was described by Celsus (ca. 30 BC – 38 AD), who divided the process into five cardinal 
signs; dolor (pain), calor (heat), rubor (redness), tumor (swelling) and functio laesa (loss of 
function), all reflecting the pathophysiology of inflammation (Figure 1). The increased blood 
flow causes the redness and increased temperature, the accumulation of fluids and mediators
causes the swelling and pain, whereas the loss of function is a consequence of it all.
Inflammation can be classified either as acute or as chronic, with different and specific 
characteristics, but both are to a large extent, local and often limited processes. Uncontrolled 
inflammatory processes may develop systemically which represent a far more dramatic 
picture, as seen in severe sepsis.
Figure 1: The five cardinal signs of inflammation: Calor, Rubor, Tumor, Dolor and Functio laesa
Innate Immunity
The principal difference between the innate and the adaptive immune system concerns the 
receptors used for the immune recognition (5). The adaptive immune system is organized 
around specialized T- and B-cells and their respective receptors, which are generated 
somatically through an ingenious process of clonal selection and constitute an enormous 
repertoire of specificities (1014 – 1018 different receptors) (5). The clonally expressed 
receptors form the basis of adaptive immunity and are essential in triggering immunological 
memory. The clonal diversity and large population of lymphocytes are essential for an 
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efficient immune response, but the adaptive immune system is not called into play until after 
several days, leaving the host defenseless (6).
The receptors of the innate immune system are germ-line encoded, implying that the 
specificity of each of the receptors is genetically determined (7). These receptors have 
evolved through evolution, thus reflecting an older defense strategy. Instead of recognizing 
detailed specific features of a pathogen, the system relies on recognizing conserved molecular 
patterns of exogenous as well as endogenous origin (7,8). The recognition proteins of innate 
immunity are accordingly called pattern-recognition receptors (PRRs). The inflammatory 
inducers of non-self-derived patterns of microbes are commonly referred to as pathogen 
associated molecular patterns (PAMPs) (7,9). The counterpart, patterns of self, refers
originally to damage -associated molecular patterns (DAMPs) or “alarmins” (10-12). In recent 
times, DAMPs has been given a wider meaning by also referring to danger associated 
molecular patterns. The terminology at this point is somewhat confusing, mixing danger and 
damage and needs to be elucidated shortly. According to the “danger model” introduced by 
Matzinger (10,13) immunity is not designed to discriminate between self and non-self, but to 
recognize danger-associated molecular patterns irrespective of their nature. In other words, 
immunity is primarily engaged in protecting the host from danger rather than in recognizing 
foreignness. As a consequence, a microbial derived pattern or tissue trauma may trigger 
similar innate immunity pathways. In the present Thesis the term DAMPs refers to danger of 
exogenous as well as endogenous origin.
PRRs are expressed on many effector cells, such as macrophages, dendritic cells and 
neutrophils but are also present as secreted proteins that act as soluble pattern recognition 
molecules (7). The Toll-like receptors belong to the most important class of PRRs and will be 
discussed later, as will the effects of the complement system, which can be regarded as a
humoral “Master Alarm System” of innate immunity (14). Examples of important 
intracellular PRRs are the NOD-like (Nucleotide Oligomerization Domian) receptors, which 
respond on both microbial and endogenous danger signals (15), and the RIG-like (Retinoic 
acid Inducible Gene) receptors, which recognize non-self RNA species from viral infections 
(16). None of these effector pathways will be discussed further in this Thesis, nor will the 
functions of the Natural killer cells, which belong to a subpopulation of cytotoxic 
lymphocytes, and which constitute an important component of innate immunity (17).
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In contrast to the adaptive immune system, innate immune pathways are fast-acting. Once 
activated, the effector cells or activated components will immediately perform their effector 
functions, such as producing and secreting signal molecules. Cytokines constitute an 
important class of inflammatory mediators with numerous and multifaceted activities. They 
activate resident cells such as fibroblasts, endothelial cells and tissue macrophages and are 
strongly involved in leukocyte recruitment through increased expression of cell surface 
molecules and chemoattraction (18). TNF-, IL-IL-6 are regarded as primary 
cytokines. These play key roles in acute inflammations and sepsis, and are known to induce 
fever- and acute phase responses among a large variety of other effects (19). Arachidonic acid 
metabolites such as prostaglandins, prostacyclins, thromboxanes and leukotrienes constitute 
another important class of inflammatory mediators that either enhance the effects of other 
mediators or directly induce diverse inflammatory effects (20). Leukotriene B4 (LTB4),
which will be discussed later in this Thesis, is a potent chemotactic agent and activator of 
white cells, in particular neutrophils. The hemostatic system is also interconnected with innate 
immune responses, is activated concurrently, and is intimately connected through mutual 
interactions, in particular to the complement system (21,22).
The complement system
The complement system (Figure 2) is an upstream arm of innate immunity and consists of 
more than 30 different plasma and cell-bound proteins (23). Several of these proteins are 
proteases and are capable of being activated by proteolytic enzymes. The precursors, so-called 
zymogens, are widely distributed in body tissue and plasma, and when activated they trigger 
an enzyme cascade reaction. The physiological effects are diverse, including recognition and 
elimination of microorganisms, disposal of waste by clearance of immune complexes and 
apoptotic cells, and working as a bridge between innate and adaptive immunity (23).
Additionally, complement also functions as an important humoral system that senses danger 
of exogenous as well as endogenous origin (24).
Activation is known to occur via three routes; the classical pathway (CP), the lectin pathway 
(LP), and the alternative pathway (AP) (25), which converge and lead to the cleavage of the 
central complement factor C3. CP activation is initiated by the binding of C1q to immune 
complexes but also when binding to other molecules such as C-reactive protein (CRP) and 
phosphatidylserine (26,27). The LP is triggered by the binding of polysaccharide structures on 
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microorganisms as well as on apoptotic cells by mannose binding lectin (MBL) or ficolins 
(28,29). Further activation of the CP and LP is closely similar, leading to the cleavage of C4 
and C2 to C4b and C2b, which together form the classical/lectin C3 convertase, C4b2b. In 
contrast to the CP and LP, the AP is not dependent on binding to a specific structure; instead, 
spontaneous hydrolysis (tickover) of C3 generates small traces of C3b, which may attach to
nearby target surfaces. Target-bound C3b binds factor B, which in turn is cleaved by factor D 
to Bb, which remains bound to C3b forming the AP C3 convertase C3bBb. Properdin is an 
important stabilizer of the AP C3 convertase, but evidence suggests that it may work as PRR 
for de novo activation of the AP (30). The C3 convertases cleave C3 at a single site, 
generating C3b and C3a. C3a is an anaphylatoxin that stimulates inflammatory processes, 
whereas C3b covalently binds to bacterial walls and acts as opsonins, thereby facilitating 
phagocytosis, or binds to C3 convertase to form C5 convertases. The terminal complement
pathway starts with the cleavage of C5, by the classical/lectin (C4bC3bC2b) or the alternative 
(C3bBb3b) C5 convertases, releasing C5a and C5b. C5b induces the assembly of the terminal 
C5b-9 complement complex (TCC), which can lyse certain pathogens and cells when 
incorporated into their lipid membranes (31). Like C3a, C5a is a potent anaphylatoxin and 
will be discussed later. The role of complement as a critical alarm system relies on the sensors 
of the distinct complement pathways, which act as soluble PRRs.
Complement activation is subjected to tight regulation by soluble and membrane-bound
inhibitors limiting deposition of complement fragments on normal cells. Several inhibitors act 
on complement convertases through promoting degradation of activated complement
fragments or by accelerating decay of the convertases (25). Pathogens are prone to 
opsonization due to the lack of these inhibitors, though many bacteria have evolved evasion 
strategies, thereby subverting complement attack (32). Excessive or inappropriate activation 
of complement may lead to tissue damage, and dysregulation of complement is associated 
with many diseases (33).
Several complement receptors are expressed on different cells, interacting with the release of 
complement fragments that make the immune system able to adapt into physiological changes 
(24). Complement receptor 1 (CR1/CD35) expressed on neutrophils and monocytes, mediates
phagocytosis, but in the circulation this receptor is predominately expressed on red cells (24).
Here, CR1 serves as a receptor for C3b-tagged immune complexes which are transferred to 
the liver and processed by macrophages. The leukocyte expressed complement receptor 3,
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(CR3)(CD11b/CD18), is an important recognition receptor of innate immunity (34). It binds 
the inactive derivate of C3b, iC3b, which on its own acts as an opsonin. In addition, CR3 
promotes leukocyte adhesion, migration and recognition of a broad range of different 
microbial molecules (34).
Figure 2. The complement System (Mollnes TE, Song WC, Lambris JD 2002. Trends Immunol 23:61-
64, with permission from Elsevier)
The anaphylatoxins of complement 
C3a and C5a are small split fragments of complement activation known as anaphylatoxins.
They both promote inflammation, in particular C5a, which is an extremely potent 
inflammatory mediator that under certain clinical conditions may cause more damage than 
help (35). A well of C5a-effects have been described: C5a promotes phagocytosis and 
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oxidative burst in neutrophils and monocytes (36), upregulates adhesion molecules and the 
cell-surface molecule CD11b (CR3) in neuthrophils (37), induces the release of granular 
enzymes, and is an important chemoattractant for neutrophils (35,38). C5a increases
trombogenicity by upregulation of tissue factor (TF) on endothelial and neutrophil cells 
(39,40). C3a causes smooth-muscle contraction (38), and both anaphylatoxins promote
vasodilation and increase capillary leakage (35). Furthermore, C3a and C5a are implicated in 
the pathogenesis of asthma; C3a by inducing mast cell degranulation and transcription factor 
activating, leading to increased inflammation (41), whereas C5a seems to play a dual role by 
limiting allergen sensitization on the one hand, and increasing inflammation on the other (42).
Interestingly, evidence suggests that the anaphyloxins are required for the survival of liver 
cells during regeneration (43). The latter fact shows that C3a and C5a have prosurvival 
properties, and do not only take part in a tissue-injury inflammatory process. The effects of 
the anaphylatoxins are mediated through the C3a receptor (C3aR) and the C5a receptors
(C5aR and C5L2), which are distributed on a variety of cells, such as myeloid-, endothelial-,
epithelial, and smooth muscle cells, as well as on different parenchyma cells (24). The 
significance and biologic role of the C5L2 receptor are debated and not fully understood,
though observations indicate that C5L2 may work as a “scavenger” receptor, thereby 
opposing the proinflammatory effects transmitted via C5aR (44,45). In contrast to the C5aR, 
the majority of the receptor is located intracellularly, and upon cell activation it is translocated 
to the cell surface (45). Interestingly, C5L2 seems to be an important ligand for the expression 
of the harmful sepsis mediator HMGB1 (46).
Toll-like receptors
Toll-like receptors (TLRs) are proteins that play key roles as PRRs. Most classes of TLRs are 
found on innate immune cells such as neutrophils, monocytes/macrophages, dendritic cells
and mast cells, but they are also widely expressed on T- and B-cells as well as on a variety of 
other cells, including endothelial cells (47). Ten different mammalian TLRs have been 
identified (48). All are classified as type 1 transmembrane proteins with an extracellular 
leucine-rich repeat domain, a signal transmembrane -helix portion, and a conserved 
intracellular TIR (Toll/IL-1R/Resistance) domain (49). Upon activation, all TLRs except for 
TLR3 recruit the adaptor molecule MyD88 for intracellular signal transduction, leading to the 
activation of the transcriptional nuclear factor-NF-), or of other transcription factors 
such as IRF3, IRF5 and AP-1, required for transcription of a wide range of inflammatory and 
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immune response genes. A MyD88 independent pathway mediates the activation of 
interferon-regulatory factors and subsequent induction of interferon- (47-49).
TLRs are located both on the cell surfaces and intracellularly on endosomal compartments;
thus, ligands of extra- and intracellular DAMPs are recognized. A broad range of different 
ligands are recognized by TLRs: bacterial cell wall components and DNA, viral, parasitic, and 
fungal products, as well as endogenously derived products such as DNA, intracellular matrix,
and proteins (47). Specific accessory proteins or co-factors regulate TLRs by contributing to 
ligand discrimination and receptor signaling (48,50). In 1998 TLR4 was demonstrated to be 
the PRRs for lipopolysaccharide (LPS) of Gram-negative bacteria (51). However, TLR4 
signaling is facilitated by the co-receptors, MD2 and CD14 (48,50). MD2 is a soluble protein 
associated with the extracellular domain of TLR4. In vivo experiments show that LPS 
responsiveness is dependent on MD2 (52), and crystal structures of TLR4-MD2 in complex 
with LPS have displayed how MD2 facilitates and potentiates TLR4 signaling by bridging 
two TLR4 molecules (53).
CD14 - the key accessory molecule
CD14 is present as a soluble protein in the blood, or as membrane bound protein to myeloid 
cells. This accessory molecule enhances LPS responsiveness by facilitating the transfer of 
LPS from LPS-binding protein to TLR4-MD2 complexes. There are two different types of 
LPS, rough and smooth, and the latter is the most common form expressed by Gram-negative 
bacteria. CD14 seems to be required for transmission of both types of LPS, whereas rough 
LPS imparts the ability to transfer TLR4 signaling independent of CD14 (54). Besides 
interacting with TLR4, CD14 works as an accessory molecule in relation to other TLRs 
(TLR2, TLR3, TLR5, TLR7 and TLR9) and has the ability to bind a variety of microbial 
products (48). Thus, CD14 is a unique upstream and promiscuous molecule, implicated in 
different TLRs-signaling reacting with a number of ligands with low affinity, and transferring 
the ligand to receptors with a higher degree of specificity and affinity.
The presence of TLRs on endothelial cells and mucosal epithelial cells in the respiratory and 
gastrointestinal tract is of great importance in host defense. Activation leads to upregulation 
of adhesion molecules, and to secretion of chemokines which are required for adequate 
migration of neutrophil cells.
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Hemostasis and Contact activation
Hemostasis is a sensitive and tightly regulated process, involving the coagulation, the 
fibrinolytic system, and platelet activation, as well as endothelial cells. TF is a transmembrane 
glycoprotein that, in vivo, is regarded as the key initiator of coagulation (55). TF is expressed 
by subendothelial cells that are not normally exposed to circulating blood, but disruption of 
vascular integrity exposes TF and initiates the coagulation cascade (56). The hemostasis is 
intimately connected to host defense, especially to the complement system, as several 
interactions exist between these two cascade systems (21). As previously mentioned, the 
anaphylatoxin C5a upregulates TF on endothelial and white cells, by contrast, activated 
clotting factors such as thrombin are able to cleave C5 independent of the C5 convertases
(57). The mutual interactions and almost concurrent activation of these systems force and 
favor host defense. For example, local formation of thrombi to or around the infected area 
provides a protective barrier and prevents bacterial spreading. However, uncontrolled
systemic activation may induce widespread thrombi formation and accompanying
microvascular dysfunction. 
The contact system, also known as the intrinsic pathway of coagulation, or the kallikrein-kinin 
system, can be considered an integrated part of innate immunity (58). The system plays only a 
secondary role in hemostasis but the release of kinins has a broad specter of activities 
including induction of proinflammatory reactions and regulation of blood pressure (59).
Activation liberates the potent proinflammatory peptide bradykinin (BK) and its metabolites 
desArgBK from high molecular-weight kininogen. BK participates in the cardinal feature of 
inflammation, producing vasodilation and increased vascular permeability, triggering the 
release of proinflammatory mediators such as histamine, prostaglandins, leukotrienes,
cytokines, and promoting neutrophil chemotaxis (60). Kinins mediate effects through two
different receptors, the B1 and B2 receptors – the former with high affinity to kinin 
metabolites, the latter with high affinity to native kinins such as BK (61). The B2 receptor is 
constitutively expressed in most tissue, particularly on endothelial cells (62), but can be 
upregulated upon inflammatory stimuli such as LPS (63). BK has a very short half-life of less 
than 30 seconds, partly due to degradation by angiotensin-converting enzyme.
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Cross-talk and redundancy of host defense
The immune system is characterized by numerous different signaling pathways that constitute
a robust and redundant host defense. The innate immune responses serve not only as a 
forceful first line defense but initiate and serve as a bridge to the adaptive immune system (9).
In response to antigen presenting cells TLR signaling is important for promoting CD4+ and 
CD8+ T lymphocyte activation (64), and certain PRR-induced cytokines (IL-12 family) may 
polarize the T cell response (65). Downstream mediators of complement activation, such as 
iC3b and C3d, enhance B cell immunity via the complement receptor CR2, and different 
mechanisms for how complement regulates T cells are also described (66). It was recently it 
was shown that T cells deficient in C3aR and C5aR displayed a weak and limited allogeneic 
host response, and blockade of C5aR reduced morbidity in a relevant mice model of acute 
graft-versus-host disease (67).
Infections are likely to induce complement- and TLR activation at the same time, suggesting 
that these responses are interconnected. In fact, these pathways are closely related through an 
extensive cross-talk (65,68). Previously it was shown that CD14 and CR3 cross-talk and 
promote phagocytosis of mycobacteria (69), and furthermore that C5a and C3a enhance TLR-
induced formation of proinflammatory cytokines (70). Evidence suggests a reciprocal 
interaction between C5a and TLRs (71), implying that compensatory mechanisms obviously 
play an important role in host defense.
Sepsis
Definition
In 1992, an international consensus conference provided a conceptual framework describing 
systemic complications induced by infections, and defined sepsis as the presence of infection 
and systemic inflammatory response syndrome (SIRS) (72). Two out of four criteria fulfilled
the definition of SIRS: Temperature > 38 or < 36 

!"
#
	
$
rate > 20 breaths/min or pCO2 < 4.2 kPa, WBC >12 x 109/L or < 4 x 109/L, or < 10 %  
immature forms. According to the severity of the disease sepsis was further categorized into 
severe sepsis and septic shock. Severe sepsis was defined as sepsis plus organ dysfunction, 
tissue hypoperfusion or hypotension, and septic shock as severe sepsis with hypotension but
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refractory to fluid resuscitation. These general definitions are widely used clinically and have
served as the basis for several clinical trials. They are, however, too sensitive and non-
specific; thus, randomized clinical trials are colored by heterogeneous patient populations 
(73). Later attempts to strengthen the sepsis criteria have been made, but no evidence has been 
found to change the definitions apart from an extended list of signs and symptoms (74). It is 
utterly important to reduce patient heterogeneity in future sepsis trials. This may be achieved 
by a different staging-system based on predisposition, insult, response and organ dysfunction 
(PIRO) (75). With respect to the biomarkers, their time course may be more reliable than the 
absolute values (76), and we definitely need more knowledge related to this dynamic process.
We still know too little about the different clinical phenotypes and associated biochemical 
profiles. This knowledge can only be achieved by large clinical trials (75).
Sepsis epidemiology
There is a relatively large variability associated with epidemiological data and sepsis. This is 
partly related to retrospective estimates and to the heterogeneous patient population. At the 
end of the last millennium the incidence of sepsis in the USA was estimated to 240 cases per 
100.000 (77), and that of severe sepsis to 95 per 100.000 (78). In two prospective studies, 
from Finland and from Australia and New Zealand, the incidence of severe sepsis was 
calculated to 38 per 100.000 adult per year and 77 per 100.000 adult per year, respectively
(79,80). The ICU mortality was found to be 15.5 % in the Finnish study, while 1-year 
mortality was 40.9 %. Other reports show a higher ICU-mortality, ranging from 26 % to 
above 50 % (80,81). The mortality reflects the severity of illness, which is clearly 
demonstrated in the large pan-European study, Sepsis Occurrence in Acutely Ill (SOAP), 
where the ICU-mortality was less than 20 % among patients with one organ failure and above 
60 % among patients with more than four organ failures (81). Different reports document that 
the proportion of patients with severe sepsis is increasing (78,82). This represents great 
clinical and economical challenges.
Pulmonary infection is the primary site of infection followed by intra-abdominal infections
(81,82). Isolation of Gram-negative bacteria is frequent and account for above 35 % of the 
isolates, and E. coli is one of the most frequent causative bacteria.
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Innate immunity and sepsis pathophysiology
The pathophysiology of sepsis is complex. The current view suggests that sepsis is unleashed 
by an infection-induced systemic inflammatory response (83,84). Under normal physiological 
conditions innate immune pathways are intended to work locally and serve host defense. By
contrast, a systemic activation of these immune defending systems may lead to a host-
threatening situation that induces a counterproductive and detrimental inflammatory response.
In other words, a systemic activation of the sensors of innate immunity, PPRs, implies loss of 
control, and a rapid and vast nonspecific response may harm the host. For instance, one of the 
primary roles of proinflammatory mediator release is to enhance leukocyte migration from 
within the blood to the site of infection. Successful activation and migration of neutrophils is 
dependent on a fine-tuned interplay with endothelial cells, involving upregulation of different 
adhesion molecules and their respective ligands (85). However, in sepsis sequestration of 
neutrophils also strikes organs not affected by infection due to impaired migration (86). As a 
consequence, neutrophil-mediated tissue injury with release of cytokines, reactive oxygen 
species, proteinases, and other cell-derived content also affects innocent or remote organs 
(87). The lungs are particularly susceptible, and impaired lung function correlates with the 
intensity of neutrophil infiltrates (88).
It is not possible to account for the complex network and myriads of mediators that play a part 
in the concert of sepsis. The picture is not uniform. In some studies the levels of 
proinflammatory mediators seem to correlate with the outcome of sepsis (89,90), and 
consumption of contact factors has been associated with a bad prognosis (91), indicating that 
septic patients are in a hyperinflammatory state. However, the heterogeneous pool of septic 
patients display different inflammatory profiles, and in some cases even a blunted response 
(92). This implies that some patients are in a hypo- rather than a hyperinflammatory state, 
reflecting the complex sepsis entity or syndrome. The release of C5a is thought to play a 
central role in the vast inflammatory drive, but generation of this anaphylatoxin is also 
associated with apoptosis of lymphocytes and other lymphoid cells (93). Although pro- and 
anti-inflammatory responses are activated initially, the proinflammatory responses are thought 
to predominate in the early phase of sepsis, whereas later phases of sepsis is featured by a 
predominant anti-inflammatory response (94). The immunosuppressive state of sepsis is 
characterized by increased susceptibility to acquiring secondary infections, as well as 
reactivation of otherwise harmless virus infections (94-96).
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From a clinical point of view, tissue hypoperfusion accompanied by multiple organ failure 
(MOF) is a key feature in severe sepsis and septic shock. Hypotension and capillary leakage
with loss of plasma fluids to the interstitial space lead to intravascular volume deficit and 
deteriorated circulation. Additionally, increased interstitial fluid accumulation and tissue 
edema negatively affect nutritional transport and oxygenation.
Dysregulated coagulation is another typical feature characterized by disseminated 
intravascular coagulation (DIC) with consumptions of platelets and widespread formation of 
intravascular microthrombi (97,98). The endothelial system in particular is an important 
component to the microvascular dysfunction, as it enhances increased adhesion of platelets 
and leukocytes and promotes vasodilation by NO production (99). Evidence suggests an 
association between severe microvascular function and fatal outcome (100). Thus, to maintain 
adequate tissue oxygen delivery and to prevent MOF, resuscitation with fluids is essential in 
the treatment of septic patients (101), and targets for early goal-directed resuscitation are
therefore specifically recommended in the international guidelines for management of severe 
sepsis and septic shock (102).
Although microbial investigations are commonly negative in these patients, early broad-
spectrum antibiotic treatment and/or surgical control of the infected area is mandatory.
Further treatment is primarily supportive, with the goal of maintaining an adequate blood
pressure, oxygen content, blood glucose level, renal function, and acid-base balance in order 
to reach a reasonable homeostasis and sustain organ functions (102). Hydrocortisone is 
recommended as adjuvant when hypotension remains poorly responsive to fluid resuscitation 
and vasoactive medication. Drotrecogin alpha activated (recombinant human activated protein 
C), which prevents formation of thrombin and has profibrinolytic properties, was added to the 
list of adjunctive therapies, but has recently been withdrawn due to failure to demonstrate
efficacy (103). Apart from significantly more advanced intensive medical services the 
causative treatment of sepsis has in general remained unchanged for the last decades.
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AIM
The aim of this Thesis was to explore the efficacy of principally different target approaches in 
Gram-negative induced inflammation and sepsis. The sensors of innate immunity pathways 
and single mediators of inflammation were targeted goals. Preclinical models were used to 
study the inflammatory reaction and effects of inhibition, ex vivo, in human and pig whole 
blood, and, in vivo, during Gram-negative induced sepsis in pigs. 
Study I. To examine the significance of the traditionally regarded early cytokines TNF- and 
IL-1, compared to the central upstream arms of innate immunity, complement, and CD14, as 
mediators of and inhibitory candidates of E. coli-induced inflammation in humans. 
Study II. To investigate the efficacy of the B2 receptor antagonist, icatibant, in a porcine 
model of Neisseria meningitidis-induced sepsis.
Study III. To investigate the efficacy of the Ornithodoros moubata Complement inhibitor 
(OmCI) in pigs and humans by using an ex vivo whole blood model for both species and an in 
vivo porcine model of E. coli-induced sepsis.
Study IV. To investigate the effect on inflammation, hemostasis and hemodynamics of OmCI 
alone, and OmCI combined with anti-CD14, in a porcine model of E. coli-induced sepsis.
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MATERIALS AND METHODS
Introduction 
Gram-negative induced inflammation in human or pig whole blood, and Gram-negative 
induced sepsis in pigs, are central and important topics for all papers discussed in this Thesis.
Both these ex vivo and in vivo induced inflammatory processes imply liberation of countless
of mediators and the involvement of numerous reactions. It is important to be aware of the 
fact that the applied methods and analyses do not elucidate this picture completely, and that 
some questions are left unanswered as a result of the selection of topics that were examined. 
On the other hand, the methods and analyses that are used are well known and regarded as 
established and reliable. The following section provides an overview of methods and analyses
that were used, as well as some related considerations. For a more detailed description of 
equipment reagents and methods, see the material and methods sections in the individual 
papers.
Bacteria and complement activators
Ex vivo (paper I and III), heat-inactivated E. coli, strain LE392 (ATCC 33572) from the 
American Type Culture Collection (Manassas, VA), was used. Heat inactivation results in 
minor alterations to the bacterial membrane, leaving the biological activity preserved but 
preventing further dividing. These bacteria were counted by flow cytometry and stored at + 4
 in batches of 1 x 109 E. coli/mL PBS. In vivo (paper III and IV), live E. coli of similar 
strain, LE392, was administered intravenously to pigs. They were stored at -&' used,
and could thereafter freely divide. The reference strain of N. meningitidis, 44/76, was used in 
paper II. This strain was originally isolated from a patient with fulminant meningococcal
septicemia in 1976. The bacteria were heat inactivated and stored at -& until used to 
induce meningococcal sepsis.
Heat-aggregated IgG (HAIGG) and zymosan, potent activators of the classical and 
lectin/alternative pathway, respectively, were used in study III to induce complement 
activation in whole blood.
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Inhibitors
In all papers, different inhibitors and respective isotype-matched or other suitable controls 
were used. Several of these were purchased, such as TNF-!	

#d
infliximab, which bind specifically to soluble and membrane bound TNF-he IL-
receptor antagonist anakinra (paper I). All three cytokine inhibitors are widely used as anti-
inflammatory therapeutics for different autoimmune disorders. The mouse anti-human CD14 
F(ab´)2 was used in paper I and III. The mouse anti-porcine CD14 monoclonal antibody clone 
MIL-2 has in previous experiments been proven to bind CD14 on porcine granulocytes and 
efficiently attenuate E. coli LPS-induced inflammation, both ex vivo and in vitro. This 
monoclonal antibody was used in paper III and IV. The selective B2 receptor antagonist, 
icatibant (paper II), has recently been made commercially available (Firazyr®), and was 
donated from Jerinin AG. Three different complement inhibitors were applied in the papers;
compstatin (paper I and III), which potently binds to and prevents cleavage of C3, eculizumab 
(Soliris®) (paper III), which is a humanized monoclonal IgG2/4k- antibody that binds to and 
prevents cleavage of the human complement factor C5, and finally the tick-derived 
Ornithodoros moubata Complement Inhibitor (OmCI) (paper III and IV), a small protein 
(16.8 kDa) that binds to and prevents cleavage of C5. The procurement of OmCI was 
particularly important, as it was demonstrated to be a very effective complement inhibitor in 
pigs and humans, and was importantly, delivered in large enough amounts to make it possible 
to carry out study IV.
Analyses
Enzyme immunoassay and multiplex technology 
Human cytokines were analyzed using multiplex technology. With this immunoassay a range 
of different biomarkers can be measured simultaneously. The technology is based on colored 
beads, each with a unique cytokine detection antibody. The beads are incubated with the 
samples, a secondary biotin-conjugated antibody is added, and finally a reporter molecule that
binds to biotin is added. The samples are run in a modified flow cytometer with two lasers, 
one that excites the beads, and one that excites the reporter molecule. In this way the beads 
are separated, and the amount of each of the cytokines can then be measured. 
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We did not have multiplex technology available for porcine cytokine analysis; instead these 
cytokines and plasminogen activator inhibitor-1 (PAI-1) were analyzed by standard individual 
commercial EIA kits. The availability of specific porcine kits is limited, making the repertoire 
of potential and interesting biomarkers restricted. However, thrombin activation in pig was 
measured in citrate plasma using a human thrombin-antithrombin (TAT) immunoassay kit 
that works for porcine plasma (104). In addition, the formation of TCC was analyzed by an 
enzyme immunoassay (EIA) previously developed in our laboratory (105). The test was 
designed for human complement activity, but was later shown to cross-react with pig (106).
The wells were coated with the mAb aE11, which is specific for a C9 neoepitope in TCC. A 
biotinylated monoclonal anti-C6 was used as detection Ab. A commercial kit was used to test
the functional activity of the CP, LP, and AP in human and pig serum. Formation of C5a in 
human plasma was analyzed by a commercial EIA. Despite several efforts with several 
different kits, we did unfortunately not manage to measure C5a in pig serum or plasma.
Leukotriene B4 (LTB4) was measured in pig and human using the same kit. 
Flow cytometry
In pig whole blood, granulocytes are clearly discriminated from mononuclear cells, but 
lymphocytes and monocytes cannot be separated by a forward/side scatter dot plot. Therefore,
the expression of tissue factor (TF) (paper IV) was measured on granulocytes, which is a bit 
unfortunate since it would have been even more interesting to look at this expression on 
monocytes. The expression of wCD11R3 (the pig ortholog to human CD11b) was measured 
on granulocytes, whereas human expression of this cell surface molecule was measured on 
granulocytes and monocyres in paper I, but only on granulocytes in study III. In study I,
oxidative burst was measured using a commercial kit.
When analyzing the expression of a surface marker on an activated cell it is important to take 
into account that the background activity can be increased. This may affect the result, 
especially for markers that are expressed at low values, which was the case for TF. In all 
analysis we used isotype controls to adjust, so that the increased expression observed is 
reliable.
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Determination of BK1-5 level and icatibant
BK is an extremely short-lived effector molecule and is rapidly metabolized to inactive 
products (107). A reasonable approach for exploring its pathophysiologic role is therefore to 
measure one of its stable metabolites, BK1-5, comprising the first five amino acids of BK
with a half-life around 90 minutes (108). Blood was drawn into a plastic syringe and 
immediately added to chilled ethanol to denature kallikrein and kinases. After one hour, the 
samples were centrifuged and the supernatant stored at -&* The samples were spiked with 
the internal standard BK1-6 and thereafter eluated, before high-performance liquid 
chromatography technique was used to determine the content of BK1-5 and icatibant.
Histopathological evaluation 
In study IV biopsies from lung and liver were formalin-fixed, and thereafter cut into thin 
sections, deparaffinized, and stained by haematoxylin/eosin (H&E) and saffron. A pathologist 
evaluated these sections in a blinded manner according to how it is described in paper IV.
The Models
Ex vivo whole blood model
In study I and III a unique ex vivo whole blood model was used. This model is extensively 
studied in human whole blood (109) and has been proven to work in pig whole blood as well 
(110,111). When developing this model, the main goal was to keep all functional effector 
systems functional and able to interact, and at the same time avoid coagulation. Commonly 
used anticoagulants, such as EDTA and citrate, inhibit complement activation, whereas 
heparin enhances complement activation at low concentrations and inhibit such activation in 
high concentrations (112). By using the specific thrombin inhibitor lepiruidin (Refludan®) no
adverse effects on complement activation were seen (109). Although the experiments 
performed in study I and III obviously lack the complexities that arise in a living organism, 
they have been performed under conditions reflecting a reliable method for studies of 
inflammatory cross-talk, where all inflammatory mediators in whole blood, except thrombin, 
are able to interact mutually (109).
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In vivo models
A large proportion of former sepsis research has been based on endotoxin models, reflecting
the fact that LPS has been recognized as a key molecule in pathogenesis of sepsis. There are 
limitations to this approach. LPS is essential to virtually all Gram-negative bacteria, and is a 
typical archetype of conserved microbial structure inducing innate immune responses. LPS 
comprises three covalently linked regions; a lipid A moiety, a core oligoisaccharide structure,
and an O-antigen polysaccharide chain. The biosynthesis of the lipid A structure varies among 
different organisms and determines the biological activity and pathogenicity of LPS (113).
LPS is known as the most potent molecule of N. meningitidis, but LPS-mutant meningococci 
strain has been shown to induce inflammation and increase mortality in a mouse model (114).
By using the same sepsis model as used in study II, our group recently demonstrated that N. 
meningitidis completely lacking LPS, induced cardiovascular and hematological changes 
comparable to those induced by an intact LPS-sufficient strain, though a 10–20-fold higher 
dose of the LPS-deficient mutant was required (115). Ex vivo experiments have revealed 
different effects of anti-CD14 and CyP (Cyanobacterial Product – which derives from blue 
green algae and inhibits TLR4/MD2), depending on whether whole blood was activated by 
whole bacteria (E. coli) or by ultrapure LPS (110,111). The effect of both inhibitors was less 
pronounced by E. coli-induced cytokine formation. Thus, the use of whole bacteria models 
encompasses apparently greater biological diversity as compared to pure endotoxin models,
and is more relevant in reflecting the magnitude of danger signals to which the host is 
exposed.
Pigs are suitable animals to use and have served as an important biomedical model for 
humans for decades, not least because several of the applied disease models using pigs are 
more relevant for the human condition. An example is the pig atherosclerosis-model, which 
facilitated analysis of disease progression and evaluation of different medications (116). The 
size of the pig allows us to use standard monitoring equipment and enables repeated blood 
sampling for comprehensive analysis. The size also makes it possible to take biopsies during 
an experiment and detailed tissue samples after euthanasia. Compared to rodents, pigs have 
the advantage of displaying relatively closer anatomical and physiological relations to 
humans, and, importantly, the pig genome has high sequence and structure homology with 
humans (117). As compared to mice, the immune parameters in pigs show closer resemblance 
to humans in more than 80 % of analyzed parameters, whereas mice show closer resemblance 
in less than 10 % (118).
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In study II, III, and IV different models of experimental induced sepsis in pigs were used. In 
study II a model of porcine meningococcal sepsis was used in the main protocol (119).
According to the procedure, the intravenous infusion rate of Neisseria meningitidis was 
doubled every 30 minutes to mimic the generation time of live Neisseria in the human 
disease. This forceful pathogenic model, expressed by a substantial plasma leakage and an 
increase in a broad specter of inflammatory parameters, parallels the changes that are 
observed in patients (119). Additionally, and as part of a supplementary project to this study, 
two pigs underwent cecal ligation and puncture (CLP)-induced sepsis, and two other pigs
underwent E. coli-induced sepsis. The polymicrobial sepsis induced by CLP was a 
modification of a previously described model (120), in which autologous feces was aspired 
from cecum, suspended in saline, and spread to all parts of peritoneum. The E. coli-induced 
sepsis model was also used in study III and IV. The model is well described and reflects an 
acute sepsis with early and rapid increase of inflammatory and hemostatic biomarkers (121).
Sepsis was induced with an increasing intravenous infusion of E. coli, and each pig received a 
total of 1.075 x 108 E. coli/kg, corresponding to 1.1 x 106 bacteria/mL blood. The E. coli that 
was used came from the same batch and was infused exactly at the same rate as when we 
previously examined the effect of anti-CD14 alone (122).
The insertion of a PiCCO catheter was implemented in all models described above. This 
thermodilution catheter enables continuous measurements of stroke volume variation (SVV),
which is a dynamic variable of fluid responsiveness and currently one of the most reliable 
hypovolemia predictors (123). The pigs were further extensively monitored. Blood gases were
regularly taken, and respirator settings adjusted to maintain a pH of 7.40, and the pigs were 
monitored with ECG, artery line, central venous catheter, and pulmonary artery catheter. The 
latter is important since pigs have resident macrophages in the lungs, closely resembling 
human Kupffer cells (124), and are extremely vulnerable to pulmonary vasoconstriction 
(125). Increased pulmonary artery pressure (MPAP) is a typical early feature of porcine sepsis 
that is probably caused by local release of a broad spectrum of endogenous metabolites (125).
An abrupt increase in MPAP was observed regularly, sometimes so severe that it was 
necessary to use norepinephrine for resuscitation. Although both the N. meningitidis and the
E. coli models showed biochemical and clinical similarities, the observed increase in MPAP is 
a feature we do not find in patients, at least not to this extent.
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Statistical considerations 
In this Thesis, several experiments revealed obvious biological effects that speak for 
themselves. One may wonder whether statistical calculations in these cases actually provided 
any more information, apart from meeting the medical scientific requirements. I therefore find 
it wise to emphasize that a statistical test can either reject or fail to reject a null hypothesis, 
but never prove that it is true. 
Parametric statistics were applied in the experiments performed in paper I, II, III, and IV. The 
results in paper I and III were statistically compared by one-way analysis of the variance 
between groups (ANOVA) with Bonferroni or Dunnet’s post-test analysis. The post-hoc 
analyses are required for comparison of three or more means, but these tests are conservative,
implying that the likelihood of making a type 1 error (rejecting the null hypothesis) decreases.
In paper II and IV the data were examined with a repeated-measures 2-way analysis of 
variance (ANOVA) followed by Bonferroni’s correction for multiple tests. In addition, a two-
sample t-test for independent samples was applied in paper II, whereas the non-parametric 
test, Kruskal-Wallis one-way analysis of variance, was used to analyze histopathological lung 
changes in paper IV. Results with a p-value <0.05 were considered as statistically significant. 
The GraphPad Prism version 5 (GraphPad Software, San Diego, CA) was used for all 
statistical analyses.
To avoid type II error and falsely maintain the null hypothesis, performing power analyses to 
predict the numbers needed to be included in a study is highly recommended. For different 
reasons we did not do this prior to the in vivo studies described in paper II and IV. The 
numbers of animals included in the different groups were defined by several factors, including 
the available amount of inhibitors, costs, logistics, and animal ethical perspectives. The latter 
is important. The purpose of using animals is to improve our understanding of biological or 
medical questions related to human or animal health, but efforts should focus on keeping the 
use of animals down to a minimum, which we have done.
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SUMMARY OF THE MAIN RESULTS
Paper I
The effect of pure rhTNF- and rhIL-1ß as inflammatory inductors in fresh human whole 
blood was explored. A modest but dose dependent increase of IL-1ß, IL-6, IL-8, MIP-1, and 
IL-1ra was induced by rhTNF-, while the effect of rhIL-1ß was limited to a modest increase 
of TNF- and IL-8. The inflammatory significance of E. coli was substantially broader and 
more potent compared to pure recombinant TNF- and IL-* As potential candidates for 
inhibition of E. coli-induced inflammation, the TNF- inhibitors, etanercept and infliximab, 
and the IL-1 receptor antagonist, anakinra, were explored. Etanercept and infliximab,
specifically binding TNF-, dose-dependently neutralized 10 ng/mL of rhTNF- added to 
whole blood. Complete neutralization was obtained by 200 μg/mL and 0.5 μg/mL whole 
blood, respectively. Anakinra does not bind IL-, and functional inhibition was measured 
using IL-8 as readout. The IL-8 concentration induced by 1 ng/mL of rhIL- was dose-
dependently decreased by anakinra and completely inhibited by 1 μg/mL whole blood.
However, inhibition of TNF- or the receptor ligand to IL-did not have any impact on 
oxidative burst or production and release of other cytokines, nor upregulation of the cell 
surface marker wCD11b. By contrast, combined inhibition of C and CD14 virtually abolished 
all measured inflammatory mediators induced by E. coli.
Paper II
The infusion of BK to anesthetized pigs caused an immediate and dose-dependent drop in 
MAP and SVRI. One μg and 100 μg of BK reduced MAP with 15 % and 48 %, respectively. 
CI increased, whereas HR and MPAP remained constant. All hemodynamic effects of 
different concentrations of BK (100, 1000 and 20 000 μg) were completely blocked by a prior 
infusion of icatibant, which is a highly selective competitive B2 receptor antagonist. The 
effect of icatibant was then investigated in a blinded randomized controlled study model of 
Gram-negative induced sepsis in pigs. N. meningitidis was infused intravenously without any 
pretreatment (n = 8), or to pigs pretreated with icatibant (n = 8). Negative controls received 
saline only. The icatibant treated group developed the same degree of severe sepsis as did the 
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positive controls. Both groups had massive capillary leakage, leukopenia, and excessive 
cytokine release.
Measurement of BK1-5 was first conducted in vitro. BK1-5 levels corresponded closely to the 
amount of exogenous BK that was added to whole blood. In vivo, after giving increasing 
bolus doses of BK greater than 100 μg, increasing amounts of BK1-5 were detected. In the 
blinded randomized controlled study of N. meningitidis-induced sepsis, BK1-5 was not 
measurable in baseline samples, but increased to an average level 1.4 + 0.8 ng/mL at 4 hours 
of sepsis. However, no differences in BK1-5 level were found between pigs receiving only 
saline, only bacteria or bacteria and icatibant. As part of a supplementary project to this study, 
two pigs underwent cecal ligation and puncture (CLP)-induced sepsis, and two pigs 
underwent E. coli-induced sepsis. BK1-5 was not detected in any of these pigs. 
Paper III
OmCI dose-dependently inhibited all three complement activation pathways similarly, and the 
inhibition was complete at a dose of 0.64 μM OmCI in both pig and human. The inhibitory 
effect of OmCI in pig and human was further demonstrated in different setups and readouts. 
OmCI dose-dependently inhibited E. coli-induced formation of TCC in whole blood. HAIGG-
and zymosan-induced TCC formation in serum was completely inhibited at 0.64 μM OmCI. 
E. coli-induced upregulation of the cell surface marker CD11b and the pig ortholog 
wCD11R3 on granulocytes were in both species dose-dependently inhibited by OmCI. In 
humans, the upregulation of CD11b was reduced by > 60 %, and in pigs the wCD11R3 was 
completely abolished at 0.32 μM OmCI. E. coli-induced IL-8 formation was inhibited in pig 
and human whole blood by OmCI alone, whereas IL-was inhibited in human whole blood
only. By using OmCI and different specific complement inhibitors this study demonstrates 
that the E. coli-induced LTB4 formation is complement dependent. However, it is known that 
OmCI captures LTB4 within an internal binding pocket, making it difficult to determine 
whether the reduced concentration of LTB4 is conditioned to direct binding or reduced 
production. Thus, increasing doses of OmCI was added to a pig and human LTB4-enriched 
plasma. OmCI dose-dependently decreased the signal in the assay, consistently with covering 
of epitopes on the leukotriene preventing it from being detected in the assay. Finally, the 
effect of OmCI on complement activity was evaluated in an E. coli sepsis model in pigs of 15 
kg. All pigs received a similar continuous infusion of OmCI (0.5 mg OmCI/h), whereas 
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different bolus doses of OmCI were tested. A bolus dose of 0.5 mg/kg completely ablated the 
classical, lectin, and alternative pathways immediately after administration and remained 
effective throughout the experiment. 
Paper IV
This study explored the effect of OmCI alone and combined with anti-CD14 on the early 
inflammatory, hemostatic, and hemodynamic responses in porcine E. coli-induced sepsis. 
Thirty pigs were randomly allocated to a negative control group (n=6), a positive control 
group (n=8), or one of two intervention groups receiving either OmCI (n=8) or OmCI and 
anti-CD14 (n=8). The OmCI dosing regimen completely ablated complement activation and 
significantly decreased the level of LTB4 in septic pigs. Granulocyte tissue factor expression, 
formation of thrombin-antithrombin complexes (p<0.001), and formation of TNF- and IL-6
(p<0.05) were efficiently inhibited by OmCI alone, and abolished or strongly attenuated by 
the combination of OmCI and anti-CD14 (p<0.001 for all). Additionally, the combined 
therapy attenuated the formation of PAI-1 (<0.05), IL-1, and IL-8, increased the formation 
of IL-10, and abolished the expression of wCD11R3 and the fall in neutrophil cell count 
(p<0.001 for all). Interestingly, OmCI combined with anti-CD14 delayed the increases in 
heart rate by 60 min (p<0.05) and mean pulmonary artery pressure by 30 min (p<0.01).
Histopathology revealed a non-significant median 60 % inhibition of lung inflammatory 
changes in the OmCl group.
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DISCUSSION
The four papers included in this Thesis explore and elucidate the significance of different 
target approaches in Gram-negative induced inflammation and sepsis. The ex vivo study 
presented in paper I, draws a clear line between inhibition of traditionally regarded early and 
central proinflammatory cytokines, versus inhibition of complement and CD14, in Gram-
negative induced inflammation. Paper II is an example of single agent intervention using 
icatibant to inhibit the effects caused by BK, recognized as an immediate mediator of 
inflammation. Paper III and IV are closely interconnected and are follow-ups of paper I. The 
data from these preclinical ex vivo inflammation studies and in vivo sepsis studies display 
clear differences, and reveal a significant distinction between the efficacies of upstream 
versus downstream inhibition of the inflammatory response.
Upstream and downstream 
Severe sepsis and septic shock are life-threatening conditions characterized by a whole-body 
inflammatory state and homeostatic imbalance (92). With early intervention one may reduce 
the companion organ failure and gain time by attenuating the detrimental inflammatory 
response. This has been and still is a major task in sepsis related research. From a historical 
perspective, much attention has been directed toward the early-appearing central 
proinflammatory cytokines. Due to their potential ability to cause endogenous harmful 
systemic effects they have been regarded as upstream mediators, but, in my opinion they 
belong to the downstream mediators of inflammation. 
Downstream inhibition
Tumor necrosis factor-alpha (TNF-) was regarded as the most important proinflammatory 
cytokine, and different observations and experimental results connected the role of TNF-
directly to the pathogenesis of sepsis. The level of TNF- correlated with the outcome of 
sepsis (89,90), administration of TNF- to animals created both cardiovascular alterations and 
inflammatory responses similar to what was seen in septic patients (126-128), and inhibition 
of TNF- protected animals against lethal effects induced by experimental sepsis (129,130).
These promising results were followed by several small and large clinical trials, but in general 
they failed to demonstrate the utility of anti-TNF-
#$#(92,131,132). An 
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additional lack of effect was also observed when trying to inhibit the effect of IL-
(133,134).
Why? This can partly be explained by a mismatch between experimental data largely obtained 
from animal research and the human course of sepsis. In mice challenged with intravenous 
infusion of LPS, an increased formation of TNF-QX
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Y	'	#
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\
was observed in clinically more relevant mouse-CLP models (135). Experiments further
showed that mice subjected to CLP-induced sepsis did not achieve improved survival by anti-
TNF-
(135,136). In humans, certain forms of sepsis, such as meningococcal 
disease, demonstrate high levels of TNF-, whereas low levels are observed among patients 
with less severe forms of sepsis (137). Evidence suggests a correlation between the severity of 
global hypoperfusion and TNF-'X'(138). This fact underscores a crucial problem related 
to running clinical sepsis trials characterized by a nonhomogenous patient population, and can 
partly explain why anti-TNF-treatment failed to that extent. In this context it is reasonable 
to note that one of the largest trials, including over 2500 patients and treated with afelimobab 
(F(ab)2 monoklonal anti-TNF-Y
^_, significantly reduced 28-days mortality by 5.8 % 
among patients stratified as IL-6 positive (139).
Paper I demonstrates that TNF-`{- are inferior inducers of inflammation compared to 
E. coli. In addition, selective inhibition of these cytokines failed to attenuate E. coli-induced 
inflammatory responses in human whole blood, whereas a profound inhibitory effect was 
observed by anti-CD14 and compstatin. There is therefore reason to presume that the rather 
disappointing effect seen by the mediator-directed therapy, i.e. proinflammatory cytokine 
inhibition, was due to the fact that the inflammatory network is broadly activated by upstream 
molecules related to recognition, limiting the effect of neutralization of single downstream 
mediators.
Upstream inhibition
The sensors of innate immunity, expressed as PRRs, are as far upstream in the inflammatory 
network as possible. As explained in the introduction they act as danger sensors, thereby 
initiating the first inflammatory stimuli, which subsequently lead to downstream cascade 
reactions. TLR-signaling is dependent on or facilitated by several accessory molecules (50).
Both MD2 and CD14 are important molecules facilitating TLR4-signaling. CD14 is an 
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archetype of an upstream recognition molecule, and has the ability to bind different microbial 
products, such as LPS, peptidoglycan and DNA (48). In addition, is also implicated as an 
accessory molecule in relation to TLR2, TLR3, TLR5, TLR7 and TLR9 (48). Thus, the 
properties of CD14 as a promiscuous upstream molecule make it an ideal target for inhibition.
The recognition molecules of complement activation, C1q, MBL, and ficolins, are selectively 
not suitable targets for a global inhibitory effect of complement. All complement pathways 
converge toward the central complement factor C3, but they do not contribute equally to 
downstream effects. The AP amplification plays a predominant role for the effects initiated by 
both the CP and the LP, being responsible for more than 80 % of TCC release in the fluid 
phase (140,141). Inhibition of the alternative pathway by targeting factor D, thereby leaving 
the CP and LP functionally preserved, is an interesting therapeutic approach. A combined 
inhibition of factor C2 and factor D to block all three initial complement pathways, or 
inhibition of C3, are methods for achieving a profound and almost complete inhibition of the 
complement system (37,142). In addition to the key role that C3 plays in the complement 
cascade, it can be regarded as a recognition molecule. Through spontaneous hydrolysis or 
tickover of C3, traces of C3b may attach to nearby target surfaces with the consequence that 
subsequent amplification of C3b deposition takes place in the absence of complement 
regulatory proteins (143). Thus, inhibition of C3 represents an ideal upstream inhibition 
target.
By targeting the terminal step in the complement pathway, C5 or its receptor(s) has a vast 
anti-inflammatory potential due to the important biologic role of C5a, and does not affect 
immunoprotective and immunoregulatory functions of upstream C3 activity (144). Although 
C5 is regarded as downstream in the complement cascade, targeting this molecule may
represent upstream inhibition. C5 is not a pattern recognition molecule but is closely 
connected to recognition, and a crucial molecule for downstream effects.
The individual sensor and effector pathways described above act as partly independent 
branches of pattern recognition. However, as mentioned in the introduction, evidence 
indicates a considerable cross-talk, implying that they can either compensate, synergize, or 
antagonize each other. Although the efficacy of selectively targeting one of these branches 
may induce a profound anti-inflammatory effect, real upstream inhibition is achieved by a 
combined inhibition due to the effect of the redundancy in host defense (68).
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Single-mediator inhibition
The historical anti-TNF-are already referred to as insufficient examples of single-
mediator intervention. Recently, eritoran tetrasodium (anti-TLR4) and drotrecogin alfa 
(activated protein C) were added to the list of unsuccessful single-mediator interventions, as 
both treatment regimens have failed to demonstrate improvement in clinical randomized trials 
(103,145).
Capillary leakage and vasodilatation are cardinal features of sepsis, and lead to intravascular 
volume deficit, hypotension, tissue edema, and deteriorated nutritional transport and tissue 
oxygenation. Attenuating the capillary leakage is a tempting approach, and BK has been a 
relevant candidate target. First, among numerous effects BK promotes capillary leakage (60);
second, evidence suggests that sepsis activates the contact system, thereby releasing excess of
BK (146-148); and third, the highly selective antagonist of the B2 receptor, icatibant 
(Firazyr®), has been proven to effectively attenuate the capillary leakage induced by 
hereditary angioedema (149).
Paper II challenges the current view of bradykinin (BK) as an important mediator of edema 
shock and inflammation in sepsis. The stable metabolite of BK, BK1-5, did not increase in 
any of the pigs subjected to either meningococcal-, E. coli-, or CLP-sepsis. In healthy 
individuals the plasma concentration of BK is reported to be 2.2 fmol/mL (150) and thus very 
low. However, in patients suffering from the deficiency disorder of C1-inhibitor, hereditary 
angioedema, BK has been measured to increase 12 times the upper limit of normal level
during attacks (150). Concerning sepsis, previous reports indicate excess BK release during 
sepsis, but these estimations are based on indirect measurements, which only state that contact 
activation has taken place. We do not have any exact data about the BK-level in septic 
conditions, but given the plethora of articles describing contact activation in sepsis we have a 
clear notion that sepsis induces BK release. It is therefore astounding that we did not find any 
increased level of BK1-5 among the septic pigs. The possibility that the measurements of 
BK1-5 were not reliable is present. Shortage of sample material from pigs entailed that we 
used human blood as surrogate matrix, which may have affected the chromatographic analysis 
and increased lower detection limit of BK1-5. Furthermore, a thorough stability test was not 
performed, which may reflect the relatively low sample yield we observed. Finally, for 
technical reasons several of the validation samples were frozen while waiting to be analyzed.
Despite this, we still have reason to suggest that the analyses were valid. Icatibant was clearly 
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demonstrated in the icatibant group only. More important, all samples taken from the pig 
receiving exogenous BK showed BK1-5 levels as expected. Similarly, the in vitro experiment 
demonstrated that the BK1-5 level corresponded closely to the amount of exogenous BK 
added to whole blood. Still, this reflects an uncertainty, and it seems imperative to proceed 
with studies and elucidate this field more closely, and, in that connection, also include 
samples from septic patients. 
If we assume that BK is generated during sepsis, paper II demonstrates no effect of blocking 
the bradykinin 2-(B2) receptor. Based on theoretical estimates, we claim that the 
concentration of icatibant given was high, also causing a 65 % to 85 % blockage of the B1 
receptor. Did we give too much icatibant? In a previous LPS-induced sepsis study on pigs, it
was found that solely inhibiting the B2 receptor increased survival (p=0.052), and improved 
all hemodynamic parameters, including a reduction of pulmonary artery pressure (151).
Interestingly, inhibition of both B1 and B2 receptors led to a worse outcome compared to the 
inhibition of the B2 receptor only. This implies that we may have masked beneficial effects in 
our own study by giving too much icatibant. However, the interplay or relation between the 
B1 and B2 receptors is complicated and difficult to penetrate, and there are indeed conflicting 
results which, are partly discussed in paper II.
Notably, the significance of BK as an important mediator in capillary leakage may easily have
been drowned out by the massive inflammation induced by the meningococcal shock.
Although BK is an immediately generated mediator in the inflammatory process, it is only 
one of many. The missing effect of icatibant joins the ranks of other interventional single 
agent studies, which in general can refer to disappointing results.
Complement inhibition and pigs
It has been challenging to find a functional complement inhibitor that could be used large-
scale in pigs. In a previous study our lab tested several candidate complement inhibitors; the 
synthetic serine protease inhibitor FUT-175, anti-factor B mAb, anti-factor D mAb, and the 
recombinant protein Vaccinia virus Complement control Protein (VCP) (152). All these 
candidates inhibited porcine complement activation to various degrees. For instance, factor B 
efficiently inhibited zymosan- and HAIGG-induced complement activation, but E. coli-
induced complement activation was insufficiently inhibited. Factor D incompletely inhibited 
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all types of complement activation. VCP was the only candidate that efficiently inhibited all
activators of complement, and was therefore found to be promising for in vivo studies.
However, the absence of large-scale supplies has prevented these experiments. Our lab has
also tested the C5 inhibitor, eculizumab (Soliris®), and the C3 inhibitor, compstatin, and 
found that none of these complement inhibitors work in pigs. The arrival of OmCI was 
therefore encouraging, particularly since we were able to use it on a large scale.
Paper III documents that OmCI efficiently inhibits all complement pathways in pigs and 
humans. As briefly discussed in paper III and IV, the effects obtained by OmCI cannot 
exclusively be attributed to complement-inhibitory effects of OmCI, since this molecule has 
bifunctional properties. Unpublished data demonstrate that the binding activities of OmCI are 
independent, and that the binding of C5 and LTB4 occurs on opposite faces of OmCI (Miles 
Nunn, personal observation). Hence, OmCI has the properties to circumvent the effects of 
TCC, C5a, and the effects of the LTB4. The arachidonic acid derived LTB4 is of vital 
importance in the early inflammatory reaction, and its action includes neutrophil chemotaxis, 
cytokine and chemokine production, secretions of granules, phagocytosis, and induction of 
oxidative burst (20,153). Evidence suggests that activities of both LTB4 and C5a are 
reciprocally enhanced. In a mice tumor protocol study, neutrophil recruitment by C5a 
required amplification via LTB4 (154), and by contrast, another mice study evaluating the 
effect of C5a receptor-inhibition on intestinal injury revealed reduced formation of LTB4 
(155). Although it seems quite obvious that the overall inflammatory power of C5a exceeds 
that of LTB4, the OmCI results from both paper III and IV are influenced by an unknown 
LTB4-inhibitory effect. In the context of attenuating the inflammatory response, this is 
presumably an advantage. 
Differential roles of complement and CD14
An unconditional comparison between paper I, III, and IV is difficult as the results reflect ex
vivo and in vivo data, and, importantly, are based on different species, human and pig. For 
instance, E. coli-induced upregulation of wCD11R3 in pig whole blood was completely 
abolished by OmCI (paper III), implying that this cell surface molecule was complement-
dependent. By contrast, no effect was observed with respect to OmCI when pigs were 
challenged with E. coli-induced sepsis (paper IV). Common to all three studies was the strong 
dependence on CD14, especially those effects related to E. coli-induced formation of 
40
cytokines. Ex vivo, anti-CD14 alone significantly and profoundly attenuated pig and human 
cytokines. The efficacy of complement inhibition was less pronounced, though several of the 
individual cytokines were significantly reduced. Combined inhibition of complement and 
CD14 essentially abolished the formation of all cytokines. In vivo (paper IV), the anti-
inflammatory effects of OmCI alone and the combined effects of OmCI and anti-CD14 
mirrored to a large extent the ex vivo observations. An additional treatment arm, exclusively 
with anti-CD14, would have improved the study by revealing the impact of anti-CD14 alone.
Due to a lack of access to anti-CD14 this could unfortunately not be done. However, historical 
data reflecting the effects of anti-CD14 alone (122) reveal effects on cytokine formation 
comparable to the ones observed by the combined treatment group (OmCI + anti-CD14). This 
gives reason to suggest that the effect of OmCI in this group was partly overwhelmed by the 
effect of anti-CD14. At the same time OmCI alone strongly reduced thrombogenicity and 
exerted pronounced anti-inflammatory effects. Despite the fact that the model was featured by 
a particularly strong dependence on CD14, this underscores the significance of complement 
and redundancy of host defense. 
Different roles of complement in E. coli- and N. meningitidis-induced inflammation have 
been comprehensively elucidated in a human ex vivo whole blood study (156). This study
demonstrated that several cell adhesion molecules and granulocyte enzyme release were 
mostly complement dependent, whereas the majority of the proinflammatory cytokines were
primarily dependent on CD14. Recently, the significance of complement was also 
demonstrated in a model of E. coli-induced sepsis in baboons, as complement inhibition 
displayed broad anti-inflammatory effects, partially reversed microcirculatory dysfunction,
and prevented systemic blood pressure falling (157).
Notably, complement may be relatively more important in other sepsis models or other types 
of experimentally induced inflammation. For instance, the significance of C5a has been 
broadly uncovered in polymicrobial sepsis in rodents, induced by CLP (cecal ligation and 
puncture) (93). Inhibition of C5a or one or both of its receptors are all target-strategies that 
have been demonstrated to reduce inflammation and increased survival among rodents 
subjected to this type of abdominal sepsis (158,159). Preliminary data from our own lab 
suggest that the efficacy of complement inhibition of Gram-positive induced inflammation is
to some extent more pronounced compared to Gram-negative induced inflammation.
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Tissue ischemia is a central component of several conditions such as myocardial infarction, 
stroke, organ transplantation, and vascular surgery. Fast restoration of adequate blood flow to 
the jeopardized tissue is the primary treatment goal, however, reperfusion of ischemic tissue 
may paradoxically exacerbate tissue injury (160). Numerous reports document that 
complement inhibition attenuates ischemia-reperfusion injury, indicating that complement 
plays a pivotal role in this tissue-pathogenesis (160-162). It may be argued that the models of 
Gram-negative induced inflammation and sepsis used in this Thesis are less suitable in 
demonstrating the significance of complement, as compared to other models. Nevertheless, 
paper I, III, and IV elucidate a central role of complement in the applied models that cannot 
be ignored.
The in vivo models and intervention principle
Lacking concordance between animal studies and clinical trials is regularly observed (163).
Concerning preclinical sepsis models the picture is probably even worse. Due to the intrinsic 
complexity that arises in relation to the human syndrome of sepsis, it has been stated that 
“there is no single ideal model of shock or sepsis” (75). Nevertheless, among several 
researchers the polymicrobial model induced by CLP has been regarded as the most preferred, 
as it better mimics the human sepsis progression, including the hypo-inflammatory or 
immunosuppressive “second” state of sepsis (164). The latter is important, as modulation of 
the blunted immune response is an interesting target for intervention (165). However, the 
model of N. meningitidis-induced sepsis, which was used in this Thesis, mirrors to a large 
extent the human meningococcal disease and displays clear translational properties (119), and 
could not be replaced by a CLP-model. Besides, there are also several limitations with the 
CLP-model, not least concerning the inaccuracy with respect to controlling the magnitude of 
sepsis (164). In addition, the majority of these studies have been performed using rodents,
which do not share the same degree of similarities with humans as pigs do (see Material and 
methods.)
The applied sepsis-models of either E. coli or N. meningitidis have both definite strengths.
They are forceful in vivo models, particularly suitable for studying the initial phase of Gram-
negative shock, and demonstrate an important combined investigation of inflammation,
hemostasis, and physiology. Although the time frames in both models were compressed, they 
displayed time-dependent dynamics characteristic of shock development. Furthermore, the 
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models are well characterized and standardized, implying that the interpretation of the data 
can be integrated into a larger context. This is of significant value, and has been stated to be 
an explicit challenge with regard to preclinical models (166).
There are several limitations with the in vivo models, which should carefully be considered. 
The pigs subjected to E. coli-induced sepsis in paper IV had an average weight of 15 kg, and 
are thus comparable to small children in the clinic. The data might therefore reflect pediatric 
sepsis more than adult sepsis. In both paper II and IV the administration of inhibitors or 
treatment was given prior to the challenge of sepsis and inflammation. A prophylactic 
treatment regimen limits the clinical utility, of course. Although prophylactic treatment as 
such is widely used in modern medicine, not least antibiotics in relation to surgical procedures 
(167,168), a prophylactic treatment for sepsis is not yet an issue. Theoretically, one can 
imagine the usefulness of providing a prophylactic sepsis regimen. The combined inhibition 
of complement and CD14/TLRs was also initially proposed as a treatment strategy to the 
patients at risk (68). The challenge, however, is to determine how we identify these patients.
As already mentioned in the introduction, we do not have the tools to identify the patients at
risk, despite the availability of a large number of biomarkers (75,169). In addition, a
prophylactic treatment regimen that profoundly attenuates central arms of innate immunity 
must be provided with caution, and it necessitates a secure identification of the patients at 
risk. Thus, a prophylactic treatment regimen remains a question for the future. 
When it comes to judging the usefulness of the prophylactic treatment, we must remember 
that the primary goals of the included studies belong to the field of science exploring the 
proof of concepts. The different studies try to answer the scientific questions regarding 
whether the molecules C5, CD14, TNF-, IL-1, and BK are involved, and to what extent 
they are involved, in Gram-negative induced inflammation and/or sepsis. As part of a
preclinical investigation of sepsis and the study of the underlying mechanisms, this is of great 
importance and a prerequisite for further investigation that may explore the effect of 
postinsult inhibition or treatment (166). Interestingly, delayed administration of anti-C5a 
antibody to mice subjected to CLP-sepsis, showing obvious clinical signs of sepsis, has 
shown to increase the survival rates (158). These encouraging results should be confirmed in 
future experiments with larger animals such as pigs, thereby providing better preclinical 
evidence and information about a therapeutic window. 
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The translational advantage of the in vivo models
The close relation between inflammation and coagulation (21) was clearly demonstrated in
paper IV. The combined inhibition of C5 and CD14 had a striking anti-inflammatory effect,
totally ablated TF expression, and prevented neutropenia. OmCI alone significantly attenuated 
the formation of TNF-`{-6, reduced the expression of TF with more than 40 %, and
dampened sepsis-induced histopathological lung changes. These effects are particularly
interesting and demonstrate the remarkable and potent effect of upstream inhibition of PRRs. 
The global effects were multifaceted and attenuated some core features of sepsis; 
inflammation (138), thrombogenicity (170), neutropenia, and tissue (lung) injury (171). The 
model's ability to show these dynamic relations is a strength and indeed of translational value.
The effects of OmCI parallel those observed in a newly published report according to which 
complement inhibition partially reversed sepsis-induced leucopenia, thrombocytopenia, DIC,
and inflammatory response, and provided a substantial organ-protection (157). It is well 
established that complement promotes coagulation and thrombosis by upregulation of TF on 
neutrophils, monocytes and endothelial cells (21,40). It was recently shown that E. coli-
induced TF functional activity in plasma microparticles was primarily dependent on C5aR
(172). This may be of great importance, since the formation of microparticles seems to reflect 
the severity of DIC (97). In accordance with our observation demonstrating a total ablation of 
TF-expression by the combined inhibition of CD14 and complement, evidence also suggests 
that upregulation of TF is dependent on TLR4/MD2-signaling (173). However, other reports 
maintain that either CD14 or LPS is important for TF upregulation (172,174), suggesting that 
this must be further elucidated. I have previously commented on the anti-inflammatory effect 
of OmCI alone and the tremendous effect provided by combined inhibition by anti-CD14 and 
OmCI. The vast anticoagulant effect of the combined treatment regimen may have reinforced 
this anti-inflammatory effect due to reduced amount of coagulation/fibrinolysis proteases and 
thereby cleavage of complement factors (175).
Interpretation of the histopathological findings in paper IV appears to be somewhat difficult. 
OmCI alone seemed to reduce the sepsis-induced lung changes markedly, though these results 
were not statistically significant, whereas no similar trend was observed in the combined 
treatment group. Reduced thrombogenicity and inhibited LTB4-dependent effects would in 
both groups partially induce the same protective effects. Attenuation of wCD11R3 by the 
combined treatment regimen should presumably have a tissue-protective effect, as this 
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integrin molecule plays a critical role in sequestering neutrophils from the circulation (85).
Furthermore, the adhesions molecules VCAM and ICAM, which are important for neutrophil 
extravasation and inflammation, are upregulated on respiratory epithelium upon LPS-
stimulation (176). The question as to why we did not see any lung-protective effect of the 
combined treatment regimen, remains unanswered and a subject of speculation. Neither the 
increased numbers of neutrophils observed in this group nor a side effect conditional on the 
administration of anti-CD14 can be excluded. 
The abrupt increase in MPAP forced us to give norepinephrine as rescue medication, which 
certainly biased the hemodynamic data. It is therefore tempting to speculate that the increased
HR and MPAP observed in the combined treatment group would be further delayed or only 
limitedly increased if we had used a less forceful model. 
Thus, this in vivo study demonstrates that combined inhibition of key molecules belonging to 
the main system of recognition has the propensity to act broadly on the numerous biomarkers 
and reveal pronounced effects on downstream mediators far beyond what is achievable from 
ex vivo studies. With regard to sepsis, several authors have correctly claimed that single-
mediator directed therapy insufficiently exerts effects, or hardly exerts any effects at all, on
the complex network of mediators (177-179). This Thesis supports this notion. The ex vivo
experiments performed in paper I confirm the downstream properties of proinflammatory 
cytokines, in addition, paper II questions the significance of BK in sepsis and suggests that 
this one is of minor importance. In contrast, upstream inhibition of central pathways of innate 
immunity, complement and CD14, appears to be more of a pluri-mediator directed therapy
(Figure 3). Careful interpretation should always be made when evaluating preclinical and 
experimental data (180), however, the findings from the Thesis provide valuable insight into
the inflammatory pathways, which will guide further science. 
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Figure 3. A proposed approach for upstream target intervention of innate immunity to 
attenuate inflammation.
Future perspectives 
Administration of LPS to healthy humans induces differential expression of 3714 unique 
genes (181), reflecting the enormous complexity of the innate immune response. At the same 
time, the expression of innate immune responses seems to be regulated through a relatively 
small number of pathways, which is encouraging. In the continuing work it seems imperative 
to elucidate the efficacy of postinsult or rescue-inhibition of Gram-negative induced 
inflammation and sepsis, and explore the possibility of a potential therapeutic window. In 
principle this may be achieved by ex vivo experiments, but obviously needs further 
examination in vivo. Using a polymicrobial model induced by CLP in pigs would indeed have 
been tempting, but source demanding with respect to finances, time, and logistics. Still, I 
believe there is no way around it we are to continue down this path, and we need a more 
realistic or disease-like model for this purpose. In addition, it seems crucial to reveal the 
significance of complement and CD14 in inflammation induced by other pathogens than E. 
coli, especially Gram-positive bacteria that are the cause of a large portion of the infectious 
diseases. Although infections by microbes potently activate an inflammatory response, the 
endogenous derived inducers of inflammation may trigger a similar harmful response via the 
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same inflammatory pathways. As already mentioned with regard to complement, studies 
suggest that the TLR receptor family is implicated in myocardardial ischemia-reperfusion 
injury, especially TLR4 and TLR2 (182,183). We have established a relevant pig model of 
myocardial infarction suitable for exploring the significance of the independent branches of 
pattern recognition, complement, and CD14. In future projects, it will therefore be interesting 
to explore the efficacy of the combined inhibition of complement and CD14 in this model, but 
also in other relevant inflammatory disease models of endogenous origin.
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CONCLUSION
This Thesis clearly demonstrates a significant difference between inhibition of upstream 
versus downstream mediators of Gram-negative induced inflammation. Central 
proinflammatory cytokines such as TNF-, IL-, and IL-6, although early in the cytokine 
response, belong to the downstream actors of inflammation as compared to upstream 
mediators of recognition systems such as complement and CD14/TLRs. The tick-derived C5 
inhibitor, OmCI, was comprehensively evaluated in pigs and humans, and the data 
demonstrate an effective and comparable potency of OmCI in both species. In a preclinical 
model of Gram-negative sepsis in pigs, pretreatment with OmCI combined with anti-CD14 
displayed vast anti-inflammatory properties, reduced thrombogenicity, and delayed 
hemodynamic changes. Despite the model’s apparent dependency on CD14, OmCI alone 
markedly reduced thrombogenicity and formation of central proinflammatory cytokines. 
Although there is still a long way to go, combined inhibition of complement and CD14 
represents a potential treatment regimen in Gram-negative sepsis. Importantly, this treatment 
regimen may be an interesting treatment approach in other systemic inflammatory conditions, 
of exogenous as well as endogenous origin, as well.
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